mCRPC progression of disease after [177Lu]Lu-PSMA-617 detected on [18F]Choline: a case of PCa heterogeneity

Radioligand therapy with [177Lu]Lu-PSMA is a theranostic approach for heavily treated mCRPC patients with positive PSMA PET in the absence of relevant PSMA-negative metastases assessed through CT, MRI, bone scan or FDG PET. In this case, we described a mCRPC patient treated with RLT with discordant...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Riccardo Laudicella, Fabio Minutoli, Simona Russo, Massimiliano Siracusa, Michelangelo Bambaci, Benedetta Pagano, Sergio Baldari
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2024-05-01
Edice:	Urology Case Reports
Témata:	FDG Metastatic castration-resistant prostate cancer PRRT RLT Theranostics
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2214442024001049
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!